These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1914364)

  • 1. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
    Matsui D; Klein J; Hermann C; Grunau V; McClelland R; Chung D; St-Louis P; Olivieri N; Koren G
    Clin Pharmacol Ther; 1991 Sep; 50(3):294-8. PubMed ID: 1914364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
    Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Goddard JG; Bartlett AN; Sheppard L
    Clin Pharmacol Ther; 1990 Sep; 48(3):255-61. PubMed ID: 2401124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
    Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP
    Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients.
    Stobie S; Tyberg J; Matsui D; Fernandes D; Klein J; Olivieri N; Bentur Y; Koren G
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):602-5. PubMed ID: 8314362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
    Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
    Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator.
    Matsui D; Hermann C; Klein J; Berkovitch M; Olivieri N; Koren G
    J Clin Pharmacol; 1994 Sep; 34(9):944-9. PubMed ID: 7983239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ
    Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance assessed by the Medication Event Monitoring System.
    Olivieri NF; Matsui D; Hermann C; Koren G
    Arch Dis Child; 1991 Dec; 66(12):1399-402. PubMed ID: 1776885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
    Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
    Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
    Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
    J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
    Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.